Literature DB >> 21683373

Five primary human pancreatic adenocarcinoma cell lines established by the outgrowth method.

Felix Rückert1, Daniela Aust, Iris Böhme, Kristin Werner, Aljoscha Brandt, Eleftherios P Diamandis, Christian Krautz, Sandra Hering, Hans-Detlev Saeger, Robert Grützmann, Christian Pilarsky.   

Abstract

BACKGROUND: Pancreatic ductal adenocarcinoma is an aggressive tumor; treatment remains a challenge because of the lack of effective therapeutic strategies. Basic research in this field is dependent on the availability of model systems. New pancreatic cancer cell lines are therefore important for the study of its biology. In the present study, we report the establishment and characterization of five new pancreatic cancer cell lines (PaCaDD-43, -60, -119, -135, -137).
MATERIAL AND METHODS: All cell lines were derived from pancreatic ductal adenocarcinomas by the Dresden outgrowth protocol. The five cell lines originated from primary pancreatic tumors, lymph node metastases, or malignant pleural effusions. We characterized the cell lines by examining their morphology and their cytostructural and functional profiles.
RESULTS: All cell lines grew as adherent monolayers and were cultured in optimized Dresden-medium. The doubling time ranged from 22 to 47 h. v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations were detected in four of the five cell lines. KRAS mutations were identical between each primary tumor and the cell line derived from it. Immunohistochemical staining showed cytoplasmic expression of CK8/18, mostly membrane and partially cytoplasmic expression of E-cadherin and strong expression of ezrin in all cell lines. Three cell lines showed nuclear p53 accumulation and heterogeneous expression of vimentin. SMAD4 was heterogeneously expressed in four of the cell lines.
CONCLUSIONS: We were able to establish five new primary pancreatic carcinoma cell lines. As applicable tools for basic research, these cell lines might contribute to a better understanding and treatment of this aggressive tumor.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21683373     DOI: 10.1016/j.jss.2011.04.021

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  35 in total

1.  Isolation of Pancreatic Cancer Cells from a Patient-Derived Xenograft Model Allows for Practical Expansion and Preserved Heterogeneity in Culture.

Authors:  Kien Pham; Daniel Delitto; Andrea E Knowlton; Emily R Hartlage; Ricky Madhavan; David H Gonzalo; Ryan M Thomas; Kevin E Behrns; Thomas J George; Steven J Hughes; Shannon M Wallet; Chen Liu; Jose G Trevino
Journal:  Am J Pathol       Date:  2016-04-18       Impact factor: 4.307

2.  Antifibrotic Therapy Disrupts Stromal Barriers and Modulates the Immune Landscape in Pancreatic Ductal Adenocarcinoma.

Authors:  Kianna Y Elahi-Gedwillo; Marjorie Carlson; Jon Zettervall; Paolo P Provenzano
Journal:  Cancer Res       Date:  2018-11-06       Impact factor: 12.701

3.  Combination therapy with BPTES nanoparticles and metformin targets the metabolic heterogeneity of pancreatic cancer.

Authors:  Amira Elgogary; Qingguo Xu; Brad Poore; Jesse Alt; Sarah C Zimmermann; Liang Zhao; Jie Fu; Baiwei Chen; Shiyu Xia; Yanfei Liu; Marc Neisser; Christopher Nguyen; Ramon Lee; Joshua K Park; Juvenal Reyes; Thomas Hartung; Camilo Rojas; Rana Rais; Takashi Tsukamoto; Gregg L Semenza; Justin Hanes; Barbara S Slusher; Anne Le
Journal:  Proc Natl Acad Sci U S A       Date:  2016-08-24       Impact factor: 11.205

4.  Tumor-penetrating peptide enhances transcytosis of silicasome-based chemotherapy for pancreatic cancer.

Authors:  Xiangsheng Liu; Paulina Lin; Ian Perrett; Joshua Lin; Yu-Pei Liao; Chong Hyun Chang; Jinhong Jiang; Nanping Wu; Timothy Donahue; Zev Wainberg; Andre E Nel; Huan Meng
Journal:  J Clin Invest       Date:  2017-04-17       Impact factor: 14.808

5.  RASGRF1 Fusions Activate Oncogenic RAS Signaling and Confer Sensitivity to MEK Inhibition.

Authors:  Lisa Hunihan; Dejian Zhao; Heather Lazowski; Man Li; Yuping Qian; Laura Abriola; Yulia V Surovtseva; Viswanathan Muthusamy; Lynn T Tanoue; Bonnie E Gould Rothberg; Kurt A Schalper; Roy S Herbst; Frederick H Wilson
Journal:  Clin Cancer Res       Date:  2022-07-15       Impact factor: 13.801

6.  Development of apratoxin S10 (Apra S10) as an anti-pancreatic cancer agent and its preliminary evaluation in an orthotopic patient-derived xenograft (PDX) model.

Authors:  Weijing Cai; Ranjala Ratnayake; Michael H Gerber; Qi-Yin Chen; Yichao Yu; Hartmut Derendorf; Jose G Trevino; Hendrik Luesch
Journal:  Invest New Drugs       Date:  2018-08-03       Impact factor: 3.850

Review 7.  Preclinical models of pancreatic ductal adenocarcinoma.

Authors:  Chang-Il Hwang; Sylvia F Boj; Hans Clevers; David A Tuveson
Journal:  J Pathol       Date:  2015-11-14       Impact factor: 7.996

8.  Explant culture of sarcoma patients' tissue.

Authors:  Roman Muff; Sander M Botter; Knut Husmann; Joelle Tchinda; Philomina Selvam; Franziska Seeli-Maduz; Bruno Fuchs
Journal:  Lab Invest       Date:  2016-04-25       Impact factor: 5.662

9.  Targeting DNA Damage Response and Replication Stress in Pancreatic Cancer.

Authors:  Stephan B Dreyer; Rosie Upstill-Goddard; Viola Paulus-Hock; Clara Paris; Eirini-Maria Lampraki; Eloise Dray; Bryan Serrels; Giuseppina Caligiuri; Selma Rebus; Dennis Plenker; Zachary Galluzzo; Holly Brunton; Richard Cunningham; Mathias Tesson; Craig Nourse; Ulla-Maja Bailey; Marc Jones; Kim Moran-Jones; Derek W Wright; Fraser Duthie; Karin Oien; Lisa Evers; Colin J McKay; Grant A McGregor; Aditi Gulati; Rachel Brough; Ilirjana Bajrami; Stephan Pettitt; Michele L Dziubinski; Juliana Candido; Frances Balkwill; Simon T Barry; Robert Grützmann; Lola Rahib; Amber Johns; Marina Pajic; Fieke E M Froeling; Phillip Beer; Elizabeth A Musgrove; Gloria M Petersen; Alan Ashworth; Margaret C Frame; Howard C Crawford; Diane M Simeone; Chris Lord; Debabrata Mukhopadhyay; Christian Pilarsky; David A Tuveson; Susanna L Cooke; Nigel B Jamieson; Jennifer P Morton; Owen J Sansom; Peter J Bailey; Andrew V Biankin; David K Chang
Journal:  Gastroenterology       Date:  2020-10-09       Impact factor: 22.682

10.  Feedback within the inter-cellular communication and tumorigenesis in carcinomas.

Authors:  Felix Rückert; Robert Grützmann; Christian Pilarsky
Journal:  PLoS One       Date:  2012-05-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.